Medtronic (NYSE:MDT) announced a definitive agreement on Tuesday to acquire Scientia Vascular, a privately held medical technology firm specializing in high-performance access products for neurovascular procedures.
Esperion Therapeutics (NASDAQ:ESPR), the pharmaceutical company focused on lipid-management therapies, reported total revenue of $168.4 million for the fourth quarter, representing a 144% increase over the same period last year.
Spruce Biosciences (NASDAQ:SPRB) reported a significant reduction in annual operating expenses for 2025 on Monday, as the company successfully transitioned its clinical focus toward its enzyme replacement therapy for rare neurological disorders.
Precision BioSciences (NASDAQ:DTIL) shares are in focus after the U.S. Food and Drug Administration granted Fast Track designation to PBGENE-DMD, an investigational in vivo gene editing therapy designed to treat Duchenne muscular dystrophy (DMD).
Boundless Bio (NASDAQ:BOLD) reported a narrowed net loss for the full year 2025 and a strategic realignment of its oncology pipeline, prioritizing a novel kinesin degrader as it prepares to enter the next phase of clinical development.
Hims & Hers Health (NYSE:HIMS) shares surged as much as 52% in early trading Monday after the telehealth leader announced a surprising end to its legal battle with Novo Nordisk.
AbbVie (NYSE:ABBV) shares are in focus after the biopharmaceutical giant released positive topline results for its investigational obesity treatment, ABBV-295.
Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) reported a fourth-quarter loss that was narrower than analysts anticipated, bolstered by a significant cash injection and clinical progress in its high-priority obesity and oncology programs.
Editas Medicine (NASDAQ:EDIT) reported fourth-quarter results on Monday that significantly outpaced Wall Street projections, fueled by higher collaboration revenue and a sharp reduction in operating expenses.
Dianthus Therapeutics (NASDAQ:DNTH) is accelerating the development of its lead immunology candidate after an interim analysis of its Phase 3 CAPTIVATE trial yielded positive results earlier than anticipated.
Bristol Myers Squibb reached a major milestone in its next-generation protein degradation program on Monday, reporting that its oral CELMoD agent, mezigdomide, significantly extended the time patients lived without their cancer progressing in a pivotal Phase 3 study.
Pfizer announced positive topline results for its investigational trispecific antibody, tilrekimig, which demonstrated significant skin clearance in adults with moderate to severe eczema and paved the way for a pivotal Phase 3 study later this year.
